TECH — Bio-Techne Corporation

Bio-Techne Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $295.9 million, flat year-over-year (YoY) on both an organic and reported basis.
• Adjusted EPS: $0.46, up 10% YoY; GAAP EPS at $0.24, up from $0.22 YoY.
• Adjusted Operating Margin: 31.1%, up 100 basis points YoY.
• Adjusted Gross Margin: 68.5%, down from 70.5% YoY, attributed to unfavorable product mix.
• Operating Cash Flow: $82.4 million, with net capital expenditures of $5.9 million.
• Debt: Bank debt at $260 million, down $40 million sequentially.

2. Strategic Updates and Business Highlights

• Core Product Growth: Core reagents, assays, and diagnostic kits showed modest growth, with significant contributions from proteomic analysis instruments and spatial biology.
• Cell Therapy: Excluding two major customers with FDA Fast Track designations, cell therapy business grew nearly 30%. The company is acquiring Wilson Wolf, enhancing its cell therapy capabilities.
• Geographic Performance:
  • China: Grew mid-single digits for the third consecutive quarter.
  • APAC (excluding China): Growth approaching 20%.
  • Americas: Declined high single digits, but adjusted for cell therapy timing, showed low single-digit growth.
• Innovations: Launched new products, including the Culturex Synthetic Hydrogel for organoids and enhancements to the ProteinSimple platform.

3. Forward Guidance and Outlook

• Q3 Guidance: Anticipates organic growth to be consistent with Q2, with underlying growth (excluding customer-specific headwinds) expected to be mid-single digits.
• Fiscal 2026 Outlook: Maintains a low single-digit revenue growth outlook for the full year, with expectations for gradual improvement in Q4.
• Fiscal 2027: Confidence in a return to normalized growth rates in cell therapy and overall business recovery as headwinds abate.

4. Challenges and Points of Concern

• Emerging Biotech Market: Continued challenges with mid-single-digit declines in emerging biotech customers due to funding pressures.
• Academic Market: Modest decline in US academic business, though stabilization is noted in Europe.
• Gross Margin Pressure: Decline attributed to unfavorable product mix and customer dynamics, with expectations for gradual improvement.
• Customer-Specific Headwinds: Temporary declines in GMP reagent demand due to FDA Fast Track designations for major customers, impacting near-term revenue.

5. Notable Q&A Insights

• Growth Cadence: Analysts inquired about growth trends, with management confirming expectations for mid-single-digit growth in Q4, driven by easing headwinds.
• Gross Margin Trends: Management explained that gross margin pressures were due to unfavorable product mix and timing of orders, with expectations for improvement in the latter half of the fiscal year.
• Biotech Funding: Management noted a positive trend in biotech funding, with expectations for a six-month lag before revenue impacts are felt.
• AI Impact: Management expressed optimism about AI's potential to enhance customer demand and improve operational efficiency.

Overall, Bio-Techne's Q2 2026 results reflect a stable performance amid challenging market conditions, with strategic initiatives aimed at long-term growth and recovery in key sectors.